SPAG5 and prostate carcinoma: SPAG5 expression was gradually increased during prostate cancer progression and its level was significantly associated with lymph node metastasis, clinical stage, Gleason score, and biochemical recurrence; moreover, miR-539 can inhibit prostate cancer progression by directly targeting SPAG5 [24].